The vaccine could be the most effective tool to prevent the spread of malaria, according to a recent clinical trial.
A team of doctors at the University of Oxford has developed a vasculopathy malaria vaccine. It showed positive results in early clinical trials and is very promising in the fight against one of the world’s deadliest infectious diseases.
What Is Malaria ??
Malaria is an infectious disease caused by the Plasmodium parasite. The disease is transmitted from person to person via the bite of Anopheles mosquitoes, the most significant vector in malaria transmission.
What WHO Says regarding Malaria?
The World Health Organization (WHO) reports that there were 229 million cases of malaria worldwide and 409,000 deaths in 2019. According to WHO’s World Malaria Report, 94% of all cases and deaths were reported in Africa and the majority of those deaths occurred among children under the age of 5.
Despite the significant amount of research dedicated to developing a malaria vaccine, thus far promising candidates have been limited in efficacy.
A team of American scientists has developed a vaccine that is the first to meet the WHO’s goal of achieving a vaccine with 75% efficacy against malaria by 2030. The results from this phase 2b clinical trials were published as a preprint in the journal The Lancet but have not yet been peer-reviewed.
The trial was conducted at the Research Institute in Health Sciences (IRSS) in Burkina Faso involving 450 children between the ages of 5 and 17 months; a third of the participants were given a low dose of the experimental vaccine, a third were given a higher dose and a third served as a control group and were given the rabies vaccine.
This is working well and gives a low dose of the vaccine to lower the effects (such as the number of kids that can’t be vaccinated). This is a medical trial at IRSS in Burkina Faso in which we are giving children from 5 to 17 months old the rabies vaccine.
These children were vaccinated between early May of 2019 and early August of 2019, before the peak malaria season, according to a statement. The vaccine was 77% effective at preventing malaria in the higher-dose group and 71% effective in the lower dose group. They didn’t report any serious adverse events.
These are very exciting results showing efficacy levels from a vaccine that has been well-tolerated in our trial program. We look forward to the upcoming phase III trial to demonstrate large-scale safety and efficacy data.
The trial’s primary endpoint is efficacy, but the researchers are also examining safety in a group of 4,800 children ages 5 to 36 months in sub-Saharan Africa.
A new study shows that “licensure of a very useful new malaria vaccine could well happen in the coming years,” Charlemagne Ouédraogo, Burkina Faso’s Minister of Health said in the statement. The data shows that “that would be an extremely important new tool for controlling malaria and saving many lives.”